AstraZeneca Said to Have Explored Bristol Myers Merger (Video)

AstraZeneca is in discussions to acquire US rival Bristol Myers Squibb in a deal potentially valued at nearly $400bn. Led by CEO Pascal Soriot, the UK-based AstraZeneca, worth £196bn, aims to merge with the Princeton-headquartered BMS, valued at $133bn and known for cancer treatments. This transaction would be one of the largest pharmaceutical deals ever, creating the world’s fourth-largest drugmaker by combining the resources and market positions of both major companies.